You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal will enable PerkinElmer to grow its infectious disease testing portfolio to include latent tuberculosis detection, it said.
In PLOS this week: genomic and transcriptomic analysis of conjunctival melanoma, phylogenetic analysis of Clostridioides difficile, and more.
The researchers believe that their prototype could be the basis of a portable, point-of-care testing platform that would enable rapid testing anywhere.
The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.
The company's CEO said that its single-molecule tethering technology has demonstrated limits of detection comparable to commercial molecular tests.
The company's Q3 sales reflect ongoing demand for COVID-19 testing products and improved customer demand in other areas of the firm's portfolio.
The option was exercised under a multiyear contract between T2 Bio and BARDA valued at a total of $69 million if all options are exercised.
In Genome Biology this week: analysis of tuberculosis samples from the 1600s, tool to detect variants affecting RNA-binding protein activity, and more.
The money will be used for research and development, building a clinical laboratory network, and seeking regulatory approval.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.